![A scientist pointing to an image of a DNA chain.](/sites/default/files/2019-04/GettyImages-645455760_0.jpg)
Clinical Trial Search Results
Natural History of Wilson Disease: Registry for Patients with Wilson Disease
This study is currently enrolling.
You are invited to donate your blood, urine, research data, and related information to be stored (banked) in a research specimen/data database or bank where it can be used for future research projects. The specimens/data collec ...
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Study Title for Study Participants: Pediatric MATCH screening protocol
This study is currently enrolling.
The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that target those changes. This combination of a tumor with a mutation and a drug that aims at that muta ...
NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)
This study is currently enrolling.
The purpose of this research study is to test how safe and well-tolerated treatment with the study drug is in combination with pembrolizumab and to find out more about the side-effects. The study aims to determine the following ...
NG-641-01: A Multicentre, Open-label, Non-randomised First in Human Study of NG-641, an Oncolytic Transgene Expressing Adenoviral Vector, in Patients With Metastatic or Advanced Epithelial Tumours (STAR)
This study is currently enrolling.
The purpose of this research study is to find out the following: (1) What effects, good and/or bad, treatment with NG-641 has on you and your cancer; (2) The amount of NG-641 that can be given and/or the best timing between dos ...
NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease and type 2 diabetes.
This study is currently enrolling.
Study Purpose: The purpose of this study is to see whether CagriSema can lower kidney damage. This will be compared to the effects of semaglutide, cagrilintide and placebo. Study Duration: Approximately 35 weeks Study Commitmen ...
NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA
This study is currently enrolling.
This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer quest ...
Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)
This study is currently enrolling.
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial
This study is currently enrolling.
Our primary objective is to evaluate the efficacy of two different regimens, 81mg aspirin daily vs 81 mg aspirin BID, in providing prophylaxis against symptomatic thromboembolic events, in patients undergoing total joint arthro ...
Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
This study is currently enrolling.
This study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation after surgery be as effective ...